Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Polyclonal antibodies Stories

2014-03-13 08:28:19

SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody...

2014-02-19 08:31:36

- BioMotiv Establishes Kodosil Bio to Develop Collaboration Compounds - SAN DIEGO and CLEVELAND, Feb. 19, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound...

2014-02-07 12:39:53

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of new antibacterial therapies. The protein's unique ability to...

2014-02-06 16:26:57

LA JOLLA, Calif., Feb. 6, 2014 /PRNewswire-USNewswire/ -- A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of...

2014-01-31 23:24:23

OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays. Rockville, MD (PRWEB) January 31, 2014 Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), an approach developed by Dr. Leigh Anderson, is a novel technology that can achieve high...

2013-12-17 08:29:17

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the initiation of an antibody development program with Momenta Pharmaceuticals, Inc. focused on the development of novel antibodies against a therapeutically relevant target. Under this agreement, Momenta will pay an upfront fee to AnaptysBio in exchange for an option to acquire antibodies generated by AnaptysBio using its SHM-XEL platform against a specific...

2013-09-12 04:22:30

BREDA, the Netherlands and GHENT, Belgium, September 12, 2013 /PRNewswire/ -- - Breakthrough data to be presented during the 'Discovery on Target' conference in Boston, MA, USA on September 23, 2013 arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody(TM) technology. Nav1.7 has been thoroughly validated...

2013-08-06 04:21:26

BREDA, The Netherlands, August 6, 2013 /PRNewswire/ -- Meeting The Increasing Demand For Technologies That Enable Antibody Product Differentiation arGEN-X, a clinical stage biopharmaceutical company specialized in the creation and development of highly differentiated human antibody therapeutics, today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology,...

2013-08-05 08:28:36

NEWARK, Del., Aug. 5, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today that the US Patent and Trademark Office has allowed patent application 13/445,492 entitled "Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides." The fundamental composition of matter and method claims allowed grant important exclusivity over new, modified carrier molecules derived from iBio's proprietary iBioModulator system and their use with one or more...

2013-07-18 12:27:34

New Funding Advances Mission to Provide Flow Cytometry Users with a Solution to the 'Missing Color' Problem and for Strategic Partners a Means to Supply Antibodies with Unlimited User-Labeling Options SAN DIEGO, July 18, 2013 /PRNewswire/ -- Solulink, Inc., an emerging life science tools company with expertise in biomolecular linking, today announced the completion of a new round of equity financing. The funds will enable Solulink to accelerate the commercialization of its HybriLink...